Direct blockade of AR binding to its target genes for the treatment of advanced prostate cancer by a novel antiandrogen SBF-1
Ahmed Elgehama a, Lijun Sun c, d, Biao Yu c, Wenjie Guoa, *, Qiang Xu a, b, *
a State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
b Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China.
c State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Academy, Shanghai 200032, China
d Department of Chemistry, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230026, China
Running title: SBF-1 binds AR-DBD and serves for the treatment of prostate cancer
*Correspondence to: Qiang Xu, Ph.D
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, China. Tel/17798524467: E-mail: molpharma@163.com
Word counts: 5100